About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

New Inhaled Drug Accredited to Treat Chronic Obstructive Pulmonary Disease

by Vishnuprasad on August 1, 2014 at 6:31 PM
Font : A-A+

 New Inhaled Drug Accredited to Treat Chronic Obstructive Pulmonary Disease

The US Food and Drug Administration (FDA) has approved a new inhaler drug to treat people with chronic obstructive pulmonary disease (COPD).

According to the FDA authorities, Striverdi Respimat (olodaterol) is an inhaled medication that can also be used by patients with emphysema who are experiencing airflow obstruction.

Advertisement

The drug has been accredited for once daily use and can be utilized over a long period of time.

"The availability of this new long-term maintenance medication offers an additional treatment choices for the millions of people who suffer from COPD," noted Curtis Rosebraugh, MD, MPH, director of the Office of Drug Evaluation II in the FDA's Center for Drug Evaluation and Research in the statement.
Advertisement

As a long-acting beta adrenergic agonist (LABA) Striverdi Respimat is designed to help keep muscles around a patient's airways relaxed in order to help manage their symptoms.

The drug was examined in a study that included 1304 patients with those who were prescribed the drug showing more improvement than those taking a placebo.

Symptoms of COPD can comprise wheezing, coughing, chest tightness and shortness of breath.

According to the National Heart Lung and Blood Institute, it is the third leading cause of death in the US.

Striverdi Respimat carries a boxed caution that notes an increased risk of asthma-related deaths that comes with LABAs.

The FDA stated, the safety and effectiveness for using the drug for the treatment of asthma has not been established and it is not currently an officially accepted use. It also should not be used as a rescue therapy.


The drug is also not advised for patients with acutely deteriorating COPD as it may produce serious side effects including narrowing and obstruction of the respiratory airway (paradoxical bronchospasm) and other cardiovascular effects.

Side effects associated with the drug include runny nose, upper respiratory tract infections, bronchitis, cough, urinary tract infection, dizziness, rash, diarrhea, back pain and joint pain.

The drug is supplied by Boehringer Ingelheim Pharmaceuticals, Inc. of Ridgefield, CT. 



Source: Medindia
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Top 10 Vitamin B12 Foods for Vegetarians - Slideshow
Targeted Screening Program Beneficial for Prostate Cancer Screening
Are Menopause Symptoms Troubling You?: Try these Options
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Signature Drug Toxicity Silicosis 

Most Popular on Medindia

Post-Nasal Drip Blood Donation - Recipients Find a Doctor Selfie Addiction Calculator Noscaphene (Noscapine) Vent Forte (Theophylline) Loram (2 mg) (Lorazepam) The Essence of Yoga Pregnancy Confirmation Calculator Sinopril (2mg) (Lacidipine)

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use